HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

I Patrick Kay Selected Research

Sirolimus (Rapamycin)

8/2012Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention.
10/2009Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


I Patrick Kay Research Topics

Disease

4Myocardial Infarction
08/2012 - 08/2005
4Cardiovascular Diseases (Cardiovascular Disease)
08/2012 - 08/2005
3Thrombosis (Thrombus)
12/2009 - 10/2007
2Hyperplasia
10/2009 - 08/2005
2Coronary Disease (Coronary Heart Disease)
07/2006 - 08/2005
1Pathologic Constriction (Stenosis)
12/2009
1Neoplasms (Cancer)
12/2009
1Inflammation (Inflammations)
10/2009
1Coronary Artery Disease (Coronary Atherosclerosis)
08/2005
1Myocardial Ischemia (Ischemic Heart Diseases)
08/2005

Drug/Important Bio-Agent (IBA)

4omega-Chloroacetophenone (Mace)IBA
08/2012 - 08/2005
2Sirolimus (Rapamycin)FDA Link
08/2012 - 10/2009
2Dihydrotachysterol (AT 10)IBA
12/2009 - 10/2007
1Biomarkers (Surrogate Marker)IBA
08/2012
1pimecrolimus (Elidel)FDA Link
10/2009
1Pharmaceutical PreparationsIBA
10/2009
1Paclitaxel (Taxol)FDA LinkGeneric
10/2009
1HDL CholesterolIBA
07/2006

Therapy/Procedure

5Stents
12/2009 - 08/2005
1Percutaneous Coronary Intervention
08/2012